Enveric Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $5.54M
- P/E (TTM)
- –
- Dividend yield
- –
About Enveric Biosciences
Pharmaceutical Preparations, SIC 2834
Enveric Biosciences is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics to treat psychiatric and neurological disorders. Utilizing its drug discovery platform and proprietary Psybrary compound library, the company creates novel molecules designed to promote neuroplasticity without causing hallucinogenic effects. Its lead drug program is the EVM301 Series featuring drug candidate EB-003, a novel derivative of N,N-Dimethyltryptamine intended to engage serotonin receptors for neuropsychiatric conditions, alongside the EVM401 pipeline series. Its intended customers and partners include patients with limited therapeutic options, as well as pharmaceutical and biotechnology companies for potential development partnerships and licensing arrangements.
The company maintains corporate operations and a subsidiary presence in the United States and Canada, with its Canadian subsidiary holding certain trademark assets. Enveric Biosciences' principal executive offices and headquarters are located in Cambridge, Massachusetts.
Summary of the business section of Enveric Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Enveric Biosciences, Inc.
- Founded
- 1994
- Headquarters
- Cambridge, MA
- Address
- 245 First Street Riverview Ii 18th Floor 02142
- Phone
- (617) 444-8400
- Website
- enveric.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- ENVB
- Exchange
- Nasdaq
- IPO date
- May 4, 2015
- Shares outstanding
- 4M, Aug 12, 2026
- Public float
- $3.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Oct 28, 2025; 1-for-15 reverse, Jan 29, 2025; 1-for-15 reverse, Jan 27, 2025; 1-for-50 reverse, Aug 12, 2022; 1-for-50 reverse, Jul 15, 2022; 1-for-4 reverse, Dec 31, 2020; 1-for-25 reverse, Dec 31, 2019; 1-for-25 reverse, Nov 25, 2019
- SEC CIK
- 890821
- CUSIP
- 29405E505
- ISIN
- US29405E5050
- LEI
- 549300CATCWKUQ6G5854
- EIN
- 95-4484725
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph Edward Tucker | Chief Executive Officer, Director | 962,562 |
| Kevin Michael Coveney | Chief Financial Officer | 180,746 |
| Peter J. Facchini | Chief Innovation Officer | 559,357 |
| Michael D. Webb | Director | 26,416 |
| Frank Pasqualone | Director | 26,423 |
| Sheila DeWitt | Director | 26,306 |
| Marcus Schabacker | Director | 26,418 |
| George A. Kegler | Director | 26,418 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Joseph Tucker | – | $628.17K | $465.81K | $1 | – |
| FY2025 Peo | $879.54K | $628.17K | $465.81K | $1 | – |
| FY2024 Dr. Joseph Tucker | – | $503.73K | $376.29K | $17 | – |
| FY2024 Non Peo Neo | $376.29K | $323.67K | $376.29K | $17 | – |
| FY2024 Peo | $611.53K | $503.73K | $376.29K | $17 | – |
| FY2023 Dr. Joseph Tucker | – | $498.23K | $364.10K | $63 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of the date of this Annual Report, we employ five full-time employees and one part-time employee.”
Corporate history
Events identified from SEC filings